Stallergenes Greer

Source: Wikipedia, the free encyclopedia.
Stallergenes Greer
Company typePrivate
IndustryPharmaceutical industry
Founded2015; 9 years ago (2015)
HeadquartersBaar, Switzerland
Key people
Stefan Meister (Chairman), Michele Antonelli (Chief Executive Officer), Giampiero De Luca (Board member)
RevenueIncrease € 277 million (2018) [1]
12,8 M€ (2018)
Number of employees
1045 (2021)

Stallergenes Greer International AG is a global bio

pharmaceutical company headquartered in Baar, Switzerland, specializing in the diagnosis and treatment of respiratory allergies through immunotherapy.[2]

Stallergenes Greer International AG is the parent company of GREER Laboratories, Inc.[3] (registered office in the U.S.) and Stallergenes S.A.S. (registered office in France).[4]

With 1035 employees in 2021,[5] Stallergenes Greer operates in 19 countries.[6]

Stallergenes Greer's core manufacturing facilities are located both in Europe (Antony and Amilly in France) and in the USA (Lenoir, North Carolina and San Diego, California).[7]

History

Stallergenes was founded in 1962 by Institut Mérieux [8][9][10][11] In 2015, Stallergenes and Greer Laboratories Inc. merged to form Stallergenes Greer, "a worldwide leader in allergy immunotherapy".[12][13]

Greer was founded by R.T. Greer, a collecter of source materials (i.e.: roots, herbs, pollens) in 1904.[14]

Stallergenes Greer is a privately held company owned by B-Flexion (ex Waypoint Capital), chaired by Ernesto Bertarelli.[15]

Activity

Stallergenes Greer is specialised in allergy immunotherapy treatments. It includes Name Patient Products (NPP) which are allergen products, prepared in accordance with prescriptions for individual patients.[16]

The product portfolio covers different segments including sublingual products (Staloral®,

Oralair
®, Actair®), subcutaneous products (Alustal®/Phostal®, Alyostal®/Albey®), allergen extracts available as a bulk extract or NPP, veterinary products, testing supplies, source materials and other supplies like sterile diluents, sterile empty vials.

Board of directors

The board of directors includes:[17][18]

  • Stefan Meister, Chairman
  • Michele Antonelli, Chief Executive Officer
  • Giampero De Luca, Board member

A pharmaceutical and clinical development programme

Since 2003, Stallergenes has been involved in a clinical development programme whose objective is to develop proprietary medicines intended to cover the main allergens responsible for more than 80% of respiratory allergies. [citation needed][19]

Oralair is marketed in 22 countries and has been approved by the Food and Drug Administration in the United States.[citation needed][20][21]

The second project in this programme is the house

dust mite immunotherapy tablet Actair which is marketed in Japan, Australia, and New Zealand,[22][23] and South Korea under the brand name Actair and in Germany under the brand name Orylmyte.[24]

In 2021, Stallergenes Greer is partnering with Aptar Pharma to develop a novel connected device for allergen immunotherapy treatment delivery. It will contribute to improving adherence, thus optimising treatment outcomes.[25]

References

  1. ^ "Annual report" (PDF). stallergenesgreer.com. 2018.
  2. ^ "STALLERGENES GREER LTD". Companies House.
  3. ^ "STALLERGENES GREER LTD". Companies House.
  4. ^ "STALLERGENES SAS". infogreffe.fr.
  5. ^ "Key facts and figures". stallergenesgreer.com.
  6. ^ "Global Network | stallergenesgreer.com". www.stallergenesgreer.com. Retrieved 2020-05-21.
  7. ^ "Annual Report 2018" (PDF). 2018.
  8. ^ "Stallergenes Greer". Ville d'Antony. Archived from the original on 2019-10-25.
  9. ^ "Le leader de la lutte contre les allergies fête ses 50 ans". Le Parisien. 12 December 2012.
  10. ^ "Grand Oralair". Les Echos. 3 April 2014.
  11. ^ "COR-Stallergènes envisage des acquisitions en 2013". Challenges. 21 December 2012.
  12. ^ "Labos: fusion de Stallergenes et Greer bouclée". Le Figaro. 8 September 2015.
  13. ^ "Stallergenes and Greer to create the World Leader in Allergy Immunotherapy - Labiotech.eu". 30 June 2015.
  14. ^ "History - stallergenesgreer.com". stallergenesgreer.com.
  15. ^ "Stallergenes Greer : Waypoint détient la totalité du capital; sortie du marché ce 17 mai". 17 May 2019.
  16. ^ "Collège de la Haute Autorité de Santé - Projet de recommandation" (PDF). Haute autorité de santé. 13 December 2017.
  17. ^ "BOARD OF DIRECTORS". Retrieved 2019-10-25.
  18. ^ "Stallergenes : résultats semestriels en hausse, changement de direction". capital.fr. 30 August 2018.
  19. ^ "Stallergènes Anti-allergènes sur mesure". 30 June 2005.
  20. ^ "Aux États-Unis, Stallergenes impose ses anti-allergiques". 10 April 2014.
  21. ^ "Le spécialiste des allergies à l'assaut des Etats-Unis". 8 April 2014.
  22. ^ "Positive Outcome of European Decentralised Registration Procedure for Stallergenes Greer's Sublingual House Dust Mite Allergen Immunotherapy Tablet". financialpost. Retrieved 2021-09-14.
  23. ^ "Stallergenes Greer Announces That the Phase III Trial for Its Sublingual Allergy Immunotherapy Tablet STAGR320 to Treat House Dust Mite-Induced Allergic Rhinitis Achieved Its Primary Endpoint". Business Wire. 20 November 2018.
  24. ^ "Positive Outcome of European Decentralised Registration Procedure for Stallergenes Greer's Sublingual House Dust Mite Allergen Immunotherapy Tablet". businesswire.com. 31 May 2021.
  25. ^ "Stallergenes Greer choisit Aptar pour son dispositif médical connecté". usinenouvelle.com. 21 November 2021.

External links

Retrieved from "https://en.wikipedia.org/w/index.php?title=Stallergenes_Greer&oldid=1209385312"